POTENTIAL NEW GENETIC AND BIOCHEMICAL MARKERS OF CHRONIC KIDNEY FAILURE

2017

disease (CKD) is an important source of long-term morbidity and mortality. It has been estimated that CKD affects more than 20 million people in the United States. Given that most patients are asymptomatic until the disease has significantly progressed, they remain unaware of the condition. Thus, it is essential to have clinical practice guidelines (BIOMARKERS aimed at early detection, evaluation, diagnosis, and treatment of this condition.